Avantor, Inc. (NYSE:AVTR) Shares Bought by Wedge Capital Management L L P NC

Wedge Capital Management L L P NC increased its position in shares of Avantor, Inc. (NYSE:AVTR) by 2.6% during the fourth quarter, Holdings Channel reports. The institutional investor owned 66,068 shares of the company’s stock after buying an additional 1,677 shares during the quarter. Wedge Capital Management L L P NC’s holdings in Avantor were worth $1,392,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. State Street Corp increased its holdings in shares of Avantor by 58.0% in the 3rd quarter. State Street Corp now owns 22,368,244 shares of the company’s stock valued at $578,666,000 after acquiring an additional 8,206,695 shares during the period. Janus Henderson Group PLC boosted its position in shares of Avantor by 18.2% during the 3rd quarter. Janus Henderson Group PLC now owns 17,692,705 shares of the company’s stock worth $457,710,000 after purchasing an additional 2,719,615 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Avantor by 7.1% during the 3rd quarter. Geode Capital Management LLC now owns 11,150,788 shares of the company’s stock worth $287,791,000 after acquiring an additional 739,667 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in Avantor by 653.0% in the third quarter. The Manufacturers Life Insurance Company now owns 6,174,736 shares of the company’s stock valued at $159,740,000 after purchasing an additional 5,354,678 shares during the last quarter. Finally, CCLA Investment Management lifted its holdings in shares of Avantor by 4.5% in the fourth quarter. CCLA Investment Management now owns 5,357,703 shares of the company’s stock valued at $112,940,000 after purchasing an additional 229,199 shares in the last quarter. Institutional investors and hedge funds own 95.08% of the company’s stock.

Wall Street Analysts Forecast Growth

AVTR has been the subject of a number of analyst reports. Robert W. Baird cut their price objective on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating for the company in a research report on Monday, October 28th. Wells Fargo & Company decreased their price objective on shares of Avantor from $30.00 to $28.00 and set an “overweight” rating for the company in a research note on Monday, October 28th. Royal Bank of Canada reiterated an “outperform” rating and set a $34.00 target price on shares of Avantor in a report on Thursday, September 26th. Barclays decreased their target price on shares of Avantor from $28.00 to $25.00 and set an “overweight” rating for the company in a research note on Friday, October 25th. Finally, UBS Group reiterated a “neutral” rating and set a $25.00 target price (down from $29.00) on shares of Avantor in a research note on Friday. Three research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $27.38.

Avantor Trading Down 1.9 %

Avantor stock opened at $22.14 on Tuesday. Avantor, Inc. has a 12 month low of $19.59 and a 12 month high of $28.00. The stock has a market cap of $15.07 billion, a price-to-earnings ratio of 48.13, a price-to-earnings-growth ratio of 3.42 and a beta of 1.28. The business has a 50 day moving average price of $21.45 and a two-hundred day moving average price of $23.39. The company has a quick ratio of 1.06, a current ratio of 1.54 and a debt-to-equity ratio of 0.84.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.